The ultimate objective of the research projects in this application is to improve our understanding of, and our therapeutic options, in CLL through a coordinated investigation of the genetics, biochemistry, immunology and pharmacology of the disease and the associations between these biological parameters and clinical outcomes. Important to the success of this project is the collaboration with members of the Biostatistics Core, who will provide assistance in the design and analysis of the clinical and laboratory research projects, as well as assist in designing the further exploration of promising laboratory, genetic and demographic findings in the natural history database assembled through this Program Project. The purpose of the Biostatistics Core is to provide the following services that will be utilized by all the research projects. 1. To provide biostatistical collaboration for clinical research protocols, including all aspects of the design, conduct, analysis, and reporting of the clinical studies. 2. To provide biostatistical collaboration for all laboratory studies, including all aspects of the design, conduct, analysis, and reporting of such studies, as well as the correlation of laboratory results with clinical parameters and outcomes. 3. To provide all aspects of biostatistical assistance for exploratory and confirmatory studies using the natural history database. 4. To advice on database structure and assure easy flow of data out of the database for analysis. 5. To assist in the supervision of data management both at a central and a institutional level, in order to maintain and complete database. 6. To participate in the quality assurance programs of the CRC. 7. To work with the Consortium Director to develop guidelines and policies on data sharing and authorship, and assurance of the integrity of data used in publications. To participate in the internal scientific review of projects proposed suing the laboratory and clinical information contained in the database, as well as the tissue banking resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA081534-03S1
Application #
6477416
Study Section
Subcommittee G - Education (NCI)
Project Start
2001-07-11
Project End
2002-04-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
3
Fiscal Year
2001
Total Cost
$165,355
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Barr, Paul M; Robak, Tadeusz; Owen, Carolyn et al. (2018) Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 103:1502-1510
Kondo, K; Shaim, H; Thompson, P A et al. (2018) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32:960-970
Hasan, Md Kamrul; Yu, Jian; Widhopf 2nd, George F et al. (2018) Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood 132:170-178
Ten Hacken, Elisa; Valentin, Rebecca; Regis, Fara Faye D et al. (2018) Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3:
Gribben, John G (2018) How and when I do allogeneic transplant in CLL. Blood 132:31-39
Sivina, Mariela; Werner, Lillian; Rassenti, Laura et al. (2018) Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180:597-600
Ott, Christopher J; Federation, Alexander J; Schwartz, Logan S et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell 34:982-995.e7
Balatti, Veronica; Tomasello, Luisa; Rassenti, Laura Z et al. (2018) miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood 132:2179-2182
Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2018) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59:1427-1438
Yu, Jian; Chen, Yun; Chen, Liguang et al. (2018) Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget 9:24731-24736

Showing the most recent 10 out of 562 publications